Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis.

Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE

Original Publication: [London] : BMJ Publishing Group Ltd, 2011-

Computational Biology/*methods ; Multiparametric Magnetic Resonance Imaging/*methods ; Prostatic Neoplasms/*diagnosis ; Prostatic Neoplasms/*genetics; Genomics ; Humans ; Image-Guided Biopsy ; Male ; Neoplasm Grading ; Prostatic Neoplasms/diagnostic imaging ; Prostatic Neoplasms/pathology ; Research Design ; Risk Factors ; Tumor Burden ; Systematic Reviews as Topic

Introduction: The introduction of multiparametric MRI (mpMRI) has enabled enhanced risk stratification for men at risk of prostate cancer, through accurate prebiopsy identification of clinically significant disease. However, approximately 10%-20% of significant prostate cancer may be missed on mpMRI. It appears that the genomic basis of lesion visibility or invisibility on mpMRI may have key implications for prognosis and treatment. Here, we describe a protocol for the first systematic review and novel bioinformatic analysis of the genomic basis of prostate cancer conspicuity on mpMRI.
Methods and Analysis: A systematic search of MEDLINE, PubMed, EMBASE and Cochrane databases will be conducted. Screening, data extraction, statistical analysis and reporting will be performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Included papers will be full text articles, written between January 1980 and December 2019, comparing molecular characteristics of mpMRI-visible lesions and mpMRI-invisible lesions at the DNA, DNA-methylation, RNA or protein level. Study bias and quality will be assessed using a modified Newcastle-Ottawa score. Additionally, we will conduct a novel bioinformatic analysis of supplementary material and publicly available data, to combine transcriptomic data and reveal common pathways highlighted across studies. To ensure methodological rigour, this protocol is written in accordance with the PRISMA Protocol 2015 checklist.
Ethics and Dissemination: Ethical approval will not be required, as this is an academic review of published literature. Findings will be disseminated through publications in peer-reviewed journals, and presentations at national and international conferences.
Prospero Registration Number: CRD42019147423.
Competing Interests: Competing interests: None declared.
(© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ.)

Cochrane Database Syst Rev. 2019 Apr 25;4:CD012663. (PMID: 31022301)
J Urol. 2015 Jan;193(1):87-94. (PMID: 25079939)
BMJ. 2018 Dec 13;363:k5290. (PMID: 30545827)
Syst Rev. 2015 Jan 01;4:1. (PMID: 25554246)
N Engl J Med. 2018 May 10;378(19):1767-1777. (PMID: 29552975)
Eur Urol. 2019 Jul;76(1):18-23. (PMID: 30685078)
BJU Int. 2019 Jul;124(1):1. (PMID: 31206999)
Eur Urol Oncol. 2019 Feb;2(1):1-11. (PMID: 30929837)
Cancer Cell. 2010 Jul 13;18(1):11-22. (PMID: 20579941)
Radiology. 2019 Aug;292(2):464-474. (PMID: 31184561)
Lancet. 2017 Feb 25;389(10071):815-822. (PMID: 28110982)
Nucleic Acids Res. 2019 Jul 2;47(W1):W199-W205. (PMID: 31114916)
PLoS Comput Biol. 2012;8(2):e1002375. (PMID: 22383865)
Syst Rev. 2016 Dec 5;5(1):210. (PMID: 27919275)
EBioMedicine. 2015 Jul 29;2(9):1133-44. (PMID: 26501111)
Theranostics. 2018 Feb 12;8(7):1752-1765. (PMID: 29556354)
Cell. 2015 Nov 5;163(4):1011-25. (PMID: 26544944)

27935 United Kingdom CRUK_ Cancer Research UK; MR/S00680X/1 United Kingdom MRC_ Medical Research Council

Keywords: cancer genetics; magnetic resonance imaging; prostate disease; urological tumours

Date Created: 20200130 Date Completed: 20210205 Latest Revision: 20240210

20240210

PMC7045175

10.1136/bmjopen-2019-034611

31992607